Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The collagen binding site on the subendothelial matrix refers to specific regions within the extracellular matrix (ECM) of blood vessels, particularly exposed after vascular injury, where collagen fibers interact with circulating proteins and cells—most notably von Willebrand factor (vWF) and platelets. This interaction is crucial for initiating hemostasis by mediating platelet adhesion and aggregation at sites of vascular damage. The primary ligand is vWF, which binds to collagen types I, III, and VI. The A3 domain of vWF is critical for collagen binding, and specific sequences like RGQOGVMGF in collagen III mediate high-affinity interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen Binding Site on Subendothelial Matrix.